GSK adds vaccines with GlycoVaxyn takeout

GlaxoSmithKline plc (LSE:GSK;NYSE:GSK) paid $190 million (L124.7 million) to acquire the remaining shares of vaccine developer

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE